Ceflatonin: Phase II started

CXS began an open-label, U.S. Phase II trial in up to 77 patients. Patients will receive 24-hour IV infusion daily of 2.5 mg/m 2 of Ceflatonin for 5 days every 4 weeks, plus 400 or 600 mg Gleevec. Gle...